Literature DB >> 25293787

Implantable hearing devices: the Ototronix MAXUM system.

Stanley Pelosi1, Matthew L Carlson2, Michael E Glasscock2.   

Abstract

For many hearing-impaired individuals, the benefits of conventional amplification may be limited by acoustic feedback, occlusion effect, and/or ear discomfort. The MAXUM system and other implantable hearing devices have been developed as an option for patients who derive inadequate assistance from traditional HAs, but who are not yet candidates for cochlear implants. The MAXUM system is based on the SOUNDTEC Direct System technology, which has been shown to provide improved functional gain as well as reduced feedback and occlusion effect compared to hearing aids. This and other implantable hearing devices may have increasing importance as future aural rehabilitation options.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Conventional hearing aid; Electromagnetic ear implant; Functional gain; Implantable hearing device; Ototronix MAXUM; Residual hearing; SOUNDTEC; Word discrimination

Mesh:

Year:  2014        PMID: 25293787     DOI: 10.1016/j.otc.2014.08.003

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  4 in total

1.  Factors associated with benefit of active middle ear implants compared to conventional hearing aids.

Authors:  Theodore R McRackan; William B Clinkscales; Jayne B Ahlstrom; Shaun A Nguyen; Judy R Dubno
Journal:  Laryngoscope       Date:  2018-02-26       Impact factor: 3.325

Review 2.  Implantable hearing devices.

Authors:  Matthias Tisch
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2017-12-18

3.  The development of active middle ear implants: A historical perspective and clinical outcomes.

Authors:  Melodi Koşaner Kließ; Arne Ernst; Jan Wagner; Philipp Mittmann
Journal:  Laryngoscope Investig Otolaryngol       Date:  2018-10-06

Review 4.  Safety of active auditory implants in magnetic resonance imaging.

Authors:  Guy Fierens; Nina Standaert; Ronald Peeters; Christ Glorieux; Nicolas Verhaert
Journal:  J Otol       Date:  2021-01-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.